Steven A Rosenberg
Overview
Explore the profile of Steven A Rosenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
423
Citations
58372
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Leko V, Groh E, Levi S, Copeland A, White B, Gasmi B, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39800378
Background: The use of tumor-infiltrating T lymphocytes (TIL) that recognize cancer neoantigens has led to lasting remissions in metastatic melanoma and certain cases of metastatic epithelial cancer. For the treatment...
2.
Parkhurst M, Goff S, Lowery F, Beyer R, Halas H, Robbins P, et al.
Nat Med
. 2024 Jul;
30(9):2586-2595.
PMID: 38992129
Adoptive cell transfer (ACT) with neoantigen-reactive T lymphocytes can mediate cancer regression. Here we isolated unique, personalized, neoantigen-reactive T cell receptors (TCRs) from tumor-infiltrating lymphocytes of patients with metastatic gastrointestinal...
3.
Rosenberg S
Science
. 2024 Jul;
385(6704):25-26.
PMID: 38963837
Using a patient's lymphocytes is approved to treat melanoma and has wider applications.
4.
Van Dyke J, Rosenberg S, Crume T, Reyes N, Alexander A, Barger B, et al.
J Dev Behav Pediatr
. 2024 Jun;
45(4):e293-e301.
PMID: 38896561
Objective: Early treatment of autism spectrum disorder (ASD) can improve developmental outcomes. Children with ASD from minority families often receive services later. We explored factors related to child's age at...
5.
Levin N, Kim S, Marquardt C, Vale N, Yu Z, Sindiri S, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38816232
Background: Tumor-infiltrating lymphocytes (TILs) targeting neoantigens can effectively treat a selected set of metastatic solid cancers. However, harnessing TILs for cancer treatments remains challenging because neoantigen-reactive T cells are often...
6.
Mikkilineni L, Natrakul D, Lam N, Manasanch E, Mann J, Weissler K, et al.
Mol Ther
. 2023 Dec;
32(2):503-526.
PMID: 38155568
Multiple myeloma (MM) is a rarely curable malignancy of plasma cells. MM expresses B cell maturation antigen (BCMA). We developed a fully human anti-BCMA chimeric antigen receptor (CAR) with a...
7.
Yossef R, Krishna S, Sindiri S, Lowery F, Copeland A, Gartner J, et al.
Cancer Cell
. 2023 Dec;
41(12):2154-2165.e5.
PMID: 38039963
Circulating T cells from peripheral blood (PBL) can provide a rich and noninvasive source for antitumor T cells. By single-cell transcriptomic profiling of 36 neoantigen-specific T cell clones from 6...
8.
Hightshoe K, Gutierrez-Raghunath S, Tomcho M, Rosenberg C, Rosenberg S, Dooling-Litfin J, et al.
Fam Syst Health
. 2023 Sep;
41(3):342-357.
PMID: 37732975
Introduction: Children from disadvantaged populations receive referrals, diagnoses, and services for autism spectrum disorder (ASD) late or not at all. We describe barriers to referral for and receipt of evaluation...
9.
Parikh A, Masi R, Gasmi B, Hanada K, Parkhurst M, Gartner J, et al.
Cancer Immunol Immunother
. 2023 Jun;
72(10):3149-3162.
PMID: 37368077
Adoptive cell transfer of tumor-infiltrating lymphocytes (TIL) can mediate durable complete responses in some patients with common epithelial cancers but does so infrequently. A better understanding of T-cell responses to...
10.
Chatani P, Lowery F, Parikh N, Hitscherich K, Yossef R, Hill V, et al.
J Immunother Cancer
. 2023 May;
11(5).
PMID: 37258038
Background: Cellular immunotherapies using autologous tumor-infiltrating lymphocytes (TIL) can induce durable regression of epithelial cancers in selected patients with treatment-refractory metastatic disease. As the genetic engineering of T cells with...